These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16981805)

  • 1. What are incretins, and how will they influence the management of type 2 diabetes?
    Blonde L; Rosenstock J; Triplitt C
    J Manag Care Pharm; 2006 Sep; 12(7 Suppl A):S2-12; quiz S14-6. PubMed ID: 16981805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
    Meece J
    Curr Med Res Opin; 2007 Apr; 23(4):933-44. PubMed ID: 17407650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
    Amori RE; Lau J; Pittas AG
    JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
    Garber AJ
    Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
    Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control.
    Cohen A; Horton ES
    Curr Med Res Opin; 2007 Apr; 23(4):905-17. PubMed ID: 17407648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
    Winkler G
    Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.
    Deacon CF
    Expert Opin Investig Drugs; 2007 Apr; 16(4):533-45. PubMed ID: 17371200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating type 2 diabetes: incretin mimetics and enhancers.
    Janosz KE; Zalesin KC; Miller WM; McCullough PA
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):387-95. PubMed ID: 19808944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitagliptin (Januvia) for type 2 diabetes.
    Med Lett Drugs Ther; 2007 Jan; 49(1251):1-3. PubMed ID: 17179897
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gliptins.
    Focosi D; Kast RE; Petrini M
    Lancet; 2007 Jan; 369(9558):269-70. PubMed ID: 17258656
    [No Abstract]   [Full Text] [Related]  

  • 15. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
    Pratley RE
    J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
    [No Abstract]   [Full Text] [Related]  

  • 19. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
    Kalra S
    J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging treatments for patients with type 2 diabetes.
    Haines ST
    Diabetes Educ; 2007; 33 Suppl 5():105S-10S. PubMed ID: 17548897
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.